Page 7 of 7
Chronic lymphocytic leukemia (CLL) rarely exhibits an aggressive clinical course and its patients often have chromosomal deletions or additions. Furthermore, reciprocal translocations are barely observed in CL...
Citation: Experimental Hematology & Oncology 2012 1:28
Multiple myeloma is an incurable malignant disorder of mature B-cells that predominantly affects the elderly. The immunomodulatory drug (IMiD) thalidomide and its newer analogs demonstrate increased antitumor ...
Citation: Experimental Hematology & Oncology 2012 1:27
Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive, life-threatening disorder characterized by chronic intravascular hemolysis caused by uncontrolled complement activation. Hepatic vein thrombosis (Bud...
Citation: Experimental Hematology & Oncology 2012 1:26
Inhibitors of apoptosis (IAPs) were intensively investigated in the context of cancer where they promote tumor growth and chemoresistence. Overexpression of the IAP BIRC6 is associated with unfavorable clinical f...
Citation: Experimental Hematology & Oncology 2012 1:25
Extreme swing of phosphor from severe hyperphosphatemia to severe hypophosphatemia in a patient with blast crisis of myeloid origin was the result of imbalance between massive apoptosis of leukemic cells in th...
Citation: Experimental Hematology & Oncology 2012 1:24
The computational fluid dynamics method, which provides an estimation of the pressure drop in the airway before and after the stent implantation, is proposed in this study. This method is based on the finite v...
Citation: Experimental Hematology & Oncology 2012 1:23
The B-cell leukemia/lymphoma 11B (BCL11B) gene is a member of the BCL family which plays a crucial role in the development, proliferation, differentiation and subsequent survival of T cells. BCL11B gene altera...
Citation: Experimental Hematology & Oncology 2012 1:22
T-cell prolymphocytic leukemia (T-PLL) is a rare form of leukemia composed of mature T-cells that usually presents in older people with a median age of 65. Most cases of T-PLL will harbor chromosomal abnormali...
Citation: Experimental Hematology & Oncology 2012 1:21
Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose r...
Citation: Experimental Hematology & Oncology 2012 1:20
Two major types of amyloidosis are primary amyloidosis or amyloid light chain amyloidosis and secondary amyloidosis. Although amyloidosis involves a variety of organ systems including skin, the occurrence of b...
Citation: Experimental Hematology & Oncology 2012 1:19
The transcription factor E2F1 has been implicated in cell cycle control and DNA damage response. Paradoxically, E2F1 can promote apoptosis and function as tumor suppressor. In non-small cell lung cancer (NSCLC...
Citation: Experimental Hematology & Oncology 2012 1:18
Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intoleran...
Citation: Experimental Hematology & Oncology 2012 1:17
A 57-year-old male with a history of hypertension presented with shortness of breath, intermittent substernal chest pain, subjective fevers, and a 30-pound weight loss. He was found to have a bladder mass four...
Citation: Experimental Hematology & Oncology 2012 1:16
JAK2V617F, a gain-of-function mutant form of tyrosine kinase JAK2, is found in the majority of patients with Ph- myeloproliferative neoplasms (MPNs), a group of chronic hematological diseases that often lead t...
Citation: Experimental Hematology & Oncology 2012 1:15
Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract have undergone a remarkable evolution in how they are perceived, classified, approached, diagnosed and managed over the last 30 years....
Citation: Experimental Hematology & Oncology 2012 1:14
We present our initial experience of allogeneic stem cell transplant procedure performed between April 2004 and August 2011 for various haematological disorders. All patients with non-malignant and malignant h...
Citation: Experimental Hematology & Oncology 2012 1:13
Hematopoietic stem cells (HSCs) are rare cells that have the unique ability to self-renew and differentiate into cells of all hematopoietic lineages. The expansion of HSCs has remained an important goal to dev...
Citation: Experimental Hematology & Oncology 2012 1:12
To evaluate the efficacy of cytokine-induced killer (CIK) cell therapy in the treatment of hepatocellular carcinoma.
Citation: Experimental Hematology & Oncology 2012 1:11
Liposomal formulations of anthracyclines appear to have favorable toxicity profile when compared with conventional anthracyclines in elderly, high risk cardiac patients and patients with prior use of anthracyc...
Citation: Experimental Hematology & Oncology 2012 1:10
HevyLite™ is a new, recently developed method that facilitates separate quantification of the kappa- and lambda-bounded amounts of a given immunoglobulin (Ig). Using this method, we measured intact immunoglobu...
Citation: Experimental Hematology & Oncology 2012 1:9
A patient with acute lymphoblastic leukemia repeatedly developed hypoglycemia during chemotherapy. Comparison of serum glucose trends between chemotherapy with and without L-asparaginase (L-Asp) demonstrated a...
Citation: Experimental Hematology & Oncology 2012 1:8
T-cell Prolymphocytic leukemia (T-PLL) is a rare post-thymic T-cell malignancy that follows an aggressive clinical course. The classical presentation includes an elevated white blood cell (WBC) count with anem...
Citation: Experimental Hematology & Oncology 2012 1:7
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusi...
Citation: Experimental Hematology & Oncology 2012 1:6
Angiogenesis is essential for promoting growth and metastasis of solid tumors by ensuring blood supply to the tumor mass. Targeting angiogenesis is therefore an attractive approach to therapeutic intervention ...
Citation: Experimental Hematology & Oncology 2012 1:5
A growing body of evidence indicates that digitoxin cardiac glycoside is a promising anticancer agent when used at therapeutic concentrations. Digitoxin has a prolonged half-life and a well-established clinica...
Citation: Experimental Hematology & Oncology 2012 1:4
Citation: Experimental Hematology & Oncology 2012 1:3
Oxidative stress and redox-regulating enzymes may have roles both in lymphomagenesis and resistance to lymphoma therapy. Previous studies from the pre-rituximab era suggest that antioxidant enzyme expression i...
Citation: Experimental Hematology & Oncology 2012 1:2
As a scientific discipline, medicine can only be advanced by experimentation. Experimentation could either validate or refute a hypothesis. Unfortunately, today's publication climate strongly favors publicatio...
Citation: Experimental Hematology & Oncology 2012 1:1
Speed
32 days to first decision for reviewed manuscripts only
21 days to first decision for all manuscripts
59 days from submission to acceptance
12 days from acceptance to publication
Citation Impact
3.492 - 2-year Impact Factor
0.709 - Source Normalized Impact per Paper (SNIP)
0.941 - SCImago Journal Rank (SJR)
Usage
182,093 Downloads
64 Altmetric Mentions
